

vh2022

13th Australasian Viral Hepatitis Conference

29 – 31 May 2022

Sofitel Brisbane Central, QLD

Conference Handbook

@ashmmedia #VH2022



THANK YOU TO OUR SPONSORS & SUPPORTERS

Major Sponsors & Supporters

abbvie

Gold Sponsor



Australian Government
Department of Health

Major Supporter

Collaborators

We would like to acknowledge the generosity of our conference collaborators who provided additional funding to enable the implementation of a hybrid event format. Many of our collaborators have been involved with the conference since its creation, and thank them for their dedication to our sector, particularly over the last few years.



THANK YOU TO OUR SCHOLARSHIP SUPPORTERS

Their support provided full
and partial scholarships



Australian Government

Department of Health

.....
Supported by Commonwealth
Department of Health



.....
Supported by



.....
Supported by

CONTENTS

Conference Co-Convenors	02
Program Committee	04
Theme Committees.....	05
Invited Speakers	06
Wifi & Conference App	11
Floor Plans	12
Exhibition Directory	13
Program	19
Poster Listing	22

Published in 2022

by the Australasian Society
for HIV, Viral Hepatitis and
Sexual Health Medicine

NATIONAL OFFICE:

Level 3, 160 Clarence Street,
Sydney, NSW, Australia

M 0458 291 166

E conference@ashm.org.au

W www.ashm.org.au

ABN: 48 264 545 457

CFN: 17788

© ASHM 2022 Design and
layout by Steph Yamey
Printed by TTR Print
Management

CONFERENCE ENVIRONMENT POLICY

ASHM Conference and Events Division implements a waste-reduction policy that addresses:

- Reduce, Reuse, Recycle. This is done before, during and after each conference.
- ASHM Conference & Events Division reduces the number of printed materials by using electronic communication means wherever possible, including the website, email, online registration and abstract submission.
- ASHM Conference & Events Division monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.
- ASHM Conference & Events Division aims to research and prioritise purchasing items and equipment that support the use of recycled materials or can be recycled after use.
- ASHM Conference & Events Division will aim to ensure that recycling bins are available onsite at all events.
- ASHM Conference & Events Division will endeavor to minimise travel through the use of teleconferences instead of face-to-face meetings and holding meetings only when necessary.
- ASHM Conference & Events Division encourages all conference stakeholders to consider the environment by suggesting the following: reduction in printing requirements; recycling conference materials; and reusing conference merchandise.

CONFERENCE CO-CONVENORS



Carrie Fowlie

Carrie Fowlie is the CEO of Hepatitis Australia, the national peak body representing the state and territory hepatitis organisations and the interests of 350,000 Australians impacted by viral hepatitis. Carrie has two decades of peak body, policy and social justice experience. Her collaborative work has resulted in policy, programs and law reform consistent with the evidence and the priorities of her constituencies.



Jason Grebely

Jason Grebely is a Professor in the Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW Sydney. Jason's training and research is based in the field of epidemiology, with a specific focus on clinical epidemiology. Jason has a BSc in Biochemistry and Molecular Biology and a PhD in Pharmacology and Therapeutics, both from the University of British Columbia in Vancouver, Canada. He completed a Postdoctoral Fellowship in Clinical Epidemiology at the University of New South Wales in Sydney, Australia. Jason is also the President of the International Network on Hepatitis in Substance Users.



Mark Stoové

Mark Stoové is Head of Public Health at the Burnet Institute and has researched the transmission and impact of blood borne viruses among key risk populations for almost 20 years. A primary focus of his work is understanding the epidemiological, behavioural and biological drivers of infections and the translation of research evidence into effective public health policy and practice.

CONFERENCE CO-CONVENORS



Jess Howell

Dr Jessica Howell MBBS(Hons) FRACP PhD MSc (Epi) PGDip PH is a gastroenterologist and senior research fellow in the Department of Gastroenterology, St Vincent's Hospital Melbourne/ University of Melbourne and leads the Hepatitis B research group within the Disease Elimination program at Burnet Institute. She combines clinical, basic science, epidemiological and public health expertise in translational research projects in liver cancer and viral hepatitis, focused on marginalized populations including people who inject drugs and people from culturally and linguistically diverse communities. She currently leads several national and international multi-centre studies in rapid point-of-care diagnostics in viral hepatitis, biomarker development in liver cancer, health systems research and international health programs for viral hepatitis and liver disease in low resource settings. She is a regular invited panel for multiple national and international clinical guidelines and technical advisor to the WHO (WPRO).



Kelly Hosking

Kelly is the Director of Sexual Health and Blood Viruses for the NT Department of Health. She has a long history in SHBBV in Aboriginal and Torres Strait Islander communities and in South East Asia. She lives on beautiful Larrakia country where she has held senior nursing roles in public health, remote sexual health, primary health care – in continuous quality improvement, program management for the Hep B PAST and in COVID emergency management and preparedness. She is completing her PhD and is an investigator on several public health research projects through Menzies School of Health Research. The broad focus of Kelly's work is to improve the cascade of care for people living with chronic hepatitis B, with a foundation step of determining everyone's status and allocating a care pathway. Her passion is building the capacity of the health workforce, with a specific focus for the Aboriginal workforce, to manage and care for people living with chronic hepatitis B and to decrease shame and stigma.

PROGRAM COMMITTEE

Alexis Apostolellis

Australasian Society
for HIV, Viral Hepatitis
and Sexual Health
Medicine (ASHM)

Burglind Liddle

Australasian
Hepatology
Association (AHA)

**Edan Campbell-
O'Brien**

NACCHO

Jane Davies

Menzies School
of Health Research

Joshua Anlezark

Hepatitis Australia

Lien Tran

WHO Collaborating
Centre for Viral
Hepatitis

Loren Brener

The Centre for Social
Research in Health,
UNSW Sydney

Megan Hughes

Sexual Health
Services Tasmania

Melinda Hassall

Australasian Society
for HIV, Viral Hepatitis
and Sexual Health
Medicine (ASHM)

Olivia Cullen

Australasian
Hepatology
Association (AHA)

Phoebe Schroder

Australasian Society
for HIV, Viral Hepatitis
and Sexual Health
Medicine (ASHM)

Sami Stewart

Australasian Society
for HIV, Viral Hepatitis
and Sexual Health
Medicine (ASHM)

Scott Bowden

The Doherty Institute

Scott McGill

Australasian Society
for HIV, Viral Hepatitis
and Sexual Health
Medicine (ASHM)

Shelley Kerr

Australasian Society
for HIV, Viral Hepatitis
and Sexual Health
Medicine (ASHM)

Steph Tzanetis

Australian Injecting
and Illicit Drug Users
League (AVIL)

Susan Hay

Hepatitis Foundation
New Zealand

Sushena**Krishnaswamy**

Monash Health

Thomas Tu

Australian Centre
for HIV and Hepatitis
Virology Research
(ACH2)

Winnie Nguyen

Hepatitis Queensland

THEME COMMITTEES



Biomedical Science & Clinical Care

Catherine Ferguson

Royal Adelaide Hospital

Peter Revill

Victorian Infectious Diseases Reference Laboratory (VIDRL), Doherty Institute

Phillip Read

Sexual Health and Blood Borne Viruses - SESLHD, Kirketon Road Centre



Community & Social Research

Emily Lenton

Australian Research in Sex, Health and Society

Katelin Haynes

Hepatitis Queensland

Lise Lafferty

Centre for Social Research in Health, UNSW Sydney



Epidemiology, Public Health & Prevention

Brendan Harney

Burnet Institute

Evan Cunningham

The Kirby Institute, UNSW Sydney

Nicole Allard

WHO Collaborating Centre for Viral Hepatitis, The Doherty Institute

KEYNOTE SPEAKERS

INTERNATIONAL



Danjuma Adda

President, World Hepatitis Alliance (WHA)

Danjuma is a Nigerian prince and accomplished public health expert on a mission to raise awareness about Hepatitis and increase access to care. Danjuma is a former Executive Board Member, World Hepatitis Alliance (WHA) for African Region from 2014-2016; founder and past National Coordinator of Civil Society Network on Viral Hepatitis in Nigeria. Danjuma in 2021 assumed the role of President, World Hepatitis Alliance (WHA), UK, the first African to occupy that role in the 15 years history of the organization. The WHA is an international charity organization registered in Switzerland with an operational office in London, with over 340 member organizations in over 100 countries. Danjuma is a Senior Fellow with ASPEN Institute, US; Advisor/Member of the World Health Organizations (WHO) Strategic and Advisory Committee on HIV, Viral Hepatitis and STIs (STAC-HHS); Member AMR Advisory Group of the AMR Patient Alliance; and member of several global networking groups and an accomplished Public Speaker. Danjuma is a Hepatitis B patient, advocate and a voice for poor populations. He was infected with Hep B while in clinical rotations and then lost his own mother to the disease several years later. Danjuma wants to change the narrative about Hepatitis and raise awareness about the deadliness of the disease, while also promoting other health outcomes such as antimicrobial stewardship and patient safety.

KEYNOTE SPEAKERS

INTERNATIONAL



Jeremy Grimshaw

Senior Scientist and Professor, Ottawa Hospital Research Institute and University of Ottawa

Jeremy Grimshaw is a world leader in knowledge translation and implementation science, a rapidly emerging field with substantial impact on health services and policy research. He has devoted his career to bridging the gap between research and clinical care; by encouraging health care professionals to adopt evidence-based research, new research discoveries can be converted into improved population health and efficient health care delivery. His research explores determinants of professional and health-care system performance, evaluates dissemination and implementation strategies to improve care, and builds theoretical and methodological developments. He is a full professor in the Department of Medicine and is also cross-appointed to the School of Epidemiology and Public Health; he is a senior scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute and a Tier 1 Canada Research Chair in Health Knowledge Transfer and Uptake. He is a member of the Canadian Network on Hepatitis C.



Joseph Tucker

Associate Professor at the London School of Hygiene and Tropical Medicine and at the UNC at Chapel Hill School of Medicine

Joseph D. Tucker is an infectious diseases physician with a special interest in crowdsourcing. He is an Associate Professor at the London School of Hygiene and Tropical Medicine and at the University of North Carolina at Chapel Hill School of Medicine. His team's ongoing research investigates crowdsourcing open calls to increase hepatitis testing and community engagement. His open calls have focused on promoting diagnostics, creating people-friendly health services, and enhancing uptake of vaccines. He has contributed to several World Health Organization guidelines and serves as a member of the TDR Global Working Group. Dr. Tucker has published 419 manuscripts and led grants totaling 15M USD. Joe received his BA from Swarthmore, MD from UNC, AM (RSEA) from Harvard, and PhD from the London School of Hygiene and Tropical Medicine.



Ed Gane

University of Auckland, New Zealand

Dr. Gane is Professor of Medicine at the University of Auckland, New Zealand, and Lead Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital.

Dr Gane chairs the Ministry of Health committee responsible for HCV elimination and co-wrote the first New Zealand National HepC Action Plan.

He is an investigator for many international clinical trials with particular interest in early phase development of new direct acting antiviral therapies against chronic hepatitis C, hepatitis B, NASH and HCC. He has published over 600 papers in peer-reviewed journals. Dr Gane is current Associate Editor for the Journal of Hepatology

In 2011, Dr Gane received the New Zealand Health Research Council (NZHRC) annual Beaven Medal and in 2014, the NZHRC annual Liley Medal.

In 2011, Dr. Gane was awarded Member of the Order of New Zealand and in 2017, was named as New Zealand Innovator of the Year for his work towards HCV elimination in New Zealand.

KEYNOTE SPEAKERS

LOCAL



Carrie Fowlie

CEO, Hepatitis Australia

Carrie Fowlie is the CEO of Hepatitis Australia, the national peak body representing the state and territory hepatitis organisations and the interests of 350,000 Australians impacted by viral hepatitis. Carrie has two decades of peak body, policy and social justice experience. Her collaborative work has resulted in policy, programs and law reform consistent with the evidence and the priorities of her constituencies.



Melinda Hassall

Clinical Nurse Lead at the Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine (ASHM)

Melinda's primary focus is identifying opportunities to advance the role of nurses providing BBV and sexual health care through collaboration, education and identification of policy issues to support knowledge translation and implementation of care within our healthcare system. Melinda is a Registered Nurse, a Fellow of the Australian College of Nursing, Australasian Hepatology Association Board Secretary, holds a Graduate Certificate in Health Promotion and a Masters degree in Public Health.



Troy Combo

Aboriginal Health Plan Program Manager, Burnet Institute

Troy has a joint appointment with the Burnet Institute and is employed and based at University of Queensland, Poche Centre for Indigenous Health and is the Aboriginal Program Manager for Eliminate Hepatitis C Australia Partnership: EC Australia.

He is a Bundjalung man from the Northern NSW and with over twenty years' experience. He has held high-level positions and has managed state and national projects working for both State and National peak Aboriginal Health Organisations and Hepatitis Australia.

TEST ME. TREAT ME.

*You're Key to
HCV
elimination.*

Early identification and treatment of Hep C could help prevent progression to severe liver disease, liver cancer and death.¹⁻³

TEST YOUR PATIENTS TODAY.

For healthcare professionals.
Image included is not of a real patient.

REFERENCES: **1.** Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (June 2020). Available at: <https://ashm.blob.core.windows.net/ashmpublic/hepatitis-C-virus-infection-a-consensus-statement-Jun-2020.pdf>. Accessed: 18 March 2022. **2.** World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018. **3.** Australian Government. Fifth National Hepatitis C Strategy 2018-2022. Available at: [https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/\\$File/Hep-C-Fifth-Nat-Strategy-2018-22.pdf](https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-bbvs-1/$File/Hep-C-Fifth-Nat-Strategy-2018-22.pdf). Accessed: 18 March 2022.

ABBREVIATIONS: HCV=hepatitis C virus. Hep C=hepatitis C.

WIFI AND CONFERENCE APP

The conference app is the best way to stay informed during the conference and free to download.

Here's what you can do with the app:

- View the program by time or session, read the abstracts, make notes and let others know what you think about the session by sharing it on Twitter
- Send your questions in to be answered and discussed during sessions
- Search for speakers, read their bio and see what presentations they are giving
- View a list of all the sponsors and exhibitors and check which booths they are at
- Build your own agenda
- Send a direct message to that person you have been trying to pin down for a meeting

How do I get the app?

The app is available to download from the Apple App Store or Google Play Store.

> Search for: *'Events App by EventsAIR'*

How do I log into the app?

Once you have found the app in the App Store:

1. Install the App.
2. The first time you open the app, you will need to enter the event code: **VH2022**
3. To login, enter your primary email address and pin which you would have received in your app instructions email and final registration confirmation email.


You are all set!

If you have any questions visit the conference team located at the Registration desk!


Wi-Fi Details

Connect to:
Sofitel Conference
Wireless

Password:
VH2022



VENUE FLOOR PLAN & EXHIBITION BOOTHS



1+2 **abbvie**

3 **Medical Technologies Australia**

4 **Cepheid.**
A better way.

5 **Roche**

6 **Camarus TBC**

7 **Kirby Institute**

TT **AUSTRALASIAN
HEPATOLOGY
ASSOCIATION**

EXHIBITION DIRECTORY

Staff at the pharmaceutical company trade displays are precluded by law, and by Medicines Australia code from giving information about specific products to non-healthcare professionals.

Booth 1+2



AbbVie combines the expertise of a recognised pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world, while our services and partnerships help us create greater access and outcomes for the health of all Australians.

Booth 3



Medical Technologies Australia 2021 announces new Major Fibroscan upgrades with SmartExam now with XXL capability and CAP – Steatosis for more accurate assessment in HCV, HBV, NAFLD, ASH and NASH. Typical of Echosens constant development to improve results using the same 50 Hz frequency with faster processors and software with broader parameters.

Booth 4



Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.

Booth 5



At Roche, we drive continuous innovation, empowering healthcare professionals to face the complex challenges of infectious diseases. The infectious disease landscape is ever-changing: outbreaks, mutations, emerging pathogens, and growing antimicrobial resistances place significant pressures on health systems. Our increasingly sophisticated diagnostic tools are helping to provide relief and transform care. From the laboratory to the point of care and beyond, trusted and flexible solutions keep you at the forefront of diagnostics excellence.

Booth 6



Camurus is a Swedish research-based pharmaceutical company committed to developing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products are conceived based on the proprietary lipid-based FluidCrystal® drug delivery technologies and an extensive research and development expertise. Camurus Australia's focus is on opioid dependence, with the aim of simplifying treatment and removing the burden and stigma for patients and their families.

Booth 7



The Kirby Institute is a world-leading health research institute at UNSW Sydney. We work to eliminate infectious diseases, globally. Our specialisation is in developing health solutions for the most at-risk communities. Doing so ultimately builds a safer, healthier world for everyone.

Tabletop



The Australasian Hepatology Association (AHA) is the peak body representing Australasian hepatology nurses and allied health professionals. The AHA supports members to facilitate excellence in healthcare for the prevention and management of all liver diseases within Australasia, with active participation in the elimination of viral hepatitis, through education, resources and partnerships.

ASSOCIATED EVENTS

SUNDAY 29 MAY

National Prisons Hepatitis Network 'Speed-geeking' activity - Eliminating hepatitis C in the Australian prison sector

Time: 4:00pm – 5:30pm

Location: Sofitel Brisbane Central

The National Prisons Hepatitis Network (NPHN) will be hosting a workshop during the VH2022 Conference in Brisbane. Please join us for an afternoon of the popular interactive 'speed-geeking' discussion activity, where you can hear from experts and participate in fast-paced, small group discussions on a variety of topics relating to hepatitis C elimination in the Australian prison sector.

Welcome Reception Networking Event

Time: 5:40pm – 6:30pm

Location: Sofitel Brisbane Central

Don't miss the opportunity to catch up with colleagues and fellow delegates on the opening night of the conference.

View the conference posters and meet our exhibitors as you enjoy this free event open to all delegates.

National Consensus Statement on the Management of Hepatitis C in Australia's Prisons

Time: 5:50pm – 6:00pm

Location: Sofitel Brisbane Central

The National Prisons Hepatitis Network are pleased to launch the National Consensus Statement on the Management of Hepatitis C in Australia's Prisons at the conference networking drinks. The consensus statement makes several recommendations for best practice standards in hepatitis C prevention, testing and treatment in the prison sector based on available evidence.

ASSOCIATED EVENTS

MONDAY 30 MAY

NSW Health Sponsored Symposium – Eliminating Hepatitis C: A NSW Perspective

Time: 7:45am – 8:45am

Location: Sofitel Brisbane Central

NSW Health is committed to eliminating hepatitis C as a public health concern by 2028. This ambitious goal is driving innovative models of care, expansion of testing, policy updates as well as systems and behavioural change. NSW Health and its partners are building momentum and driving activities across prevention, testing, treatment, and to decrease stigma and discrimination.

The launch of the NSW Hepatitis C Strategy 2022 – 2025 lays the foundation for achieving elimination by 2028. This session will focus on the four pillars of prevent, test, treat, and stigma and discrimination. These pillars underpin the NSW Hepatitis C Strategy 2022 – 2025 and will drive the NSW response to hepatitis C. Come join the conversations and experiences of hepatitis C in NSW.

Gilead Sponsored Symposium - Making a cure possible for the remaining Australians living with hepatitis C

Time: 1:30pm – 2:15pm

Location: Sofitel Brisbane Central

This is a HCP only event.

ASSOCIATED EVENTS

MONDAY 30 MAY (CONT.)

Viral Hepatitis Conference Networking Dinner

Time: 7:00pm – 11:00pm

Location: The Warehouse

Website: www.thewarehousebrisbane.com.au

Delegate: AU\$66.00

Guest: AU\$88.00

Join us at The Warehouse for a stand up cocktail reception with canapes and food stations followed by dancing.

Let's celebrate seeing one another face to face again! This is a paid event. Transport to the dinner is not included.

ASSOCIATED EVENTS

TUESDAY 31 MAY

ILBIJERRI Theatre Company's VIRAL: Are You The Cure? A deadly short film about smashing Hepatitis C

Time: 1:15pm – 1:45pm

Location: Sofitel Brisbane Central

Originally staged as a play which toured in 2018 and 2019, VIRAL is a short film made with mob for mob by ILBIJERRI Theatre Company about navigating Hepatitis C.

Sifting through myths, smashing stigma, and getting the right information can seem like an impossible dream – but preventing and curing Hep C is now easier than you might think.

Join Ally and Kev who live up in the flats. They've got their own little place, a brand new baby and dreams for the future. Life should be good but sometimes things don't always go to plan. Meet Merv who hasn't been feeling great lately, not for some years in fact. Years of tough luck, bad choices and hard living have finally caught up with him.

They're all looking at one final chance to make things right before it's too late.

PROGRAM

DAY 1: SUNDAY 29 MAY

Full details on the presentations and speakers can be found in the conference app.

12.00	Registration Opens			
13.00 - 15.15	Session A: Opening Ceremony Room: Ballroom 3			
15.15 - 16.00	Afternoon Tea			
15.25 - 15.40	Poster Tour 01 Location: Posters 1 - 3			
16.00 - 17.40	Session B: Proffered Paper Session 01 Room: Ballroom 2	16.00 - 17.40	Session D: The many faces of Hepatitis B: diversity and its impact on care Room: Ballroom 3	16.00 - 17.30 National Prisons Hepatitis Network ‘Speed-geeking’ activity - Eliminating hepatitis C in the Australian prison sector Room: Ballroom 1
17.40 - 18.30	Networking Drinks			

PROGRAM

DAY 2: MONDAY 30 MAY

Full details on the presentations and speakers can be found in the conference app.

07.30	Registration Opens		
07.45 - 08.45	Sponsored Symposium - Eliminating Hepatitis C: A NSW Perspective Room: Ballroom 3		
09.00 - 11.00	Session E: Plenary 02 Room: Ballroom 3		
11.00 - 11.30	Morning Tea		
11.30 - 13.00	Session F: The road to viral hepatitis elimination – where are we and where do we go from here? Room: Ballroom 2	11.30 - 13.00	Session G: Advanced Liver Disease Room: Ballroom 3
13.00 - 14.30	Lunch		
13.30 - 14.15	Sponsored Symposium: Making a cure possible for the remaining Australians living with hepatitis C Room: Ballroom 3		
14.30 - 15.35	Session H: Proffered Paper Session 02 Room: Ballroom 2	14.30 - 15.35	Session I: Proffered Paper Session 03 Room: Ballroom 3
15.35 - 16.15	Afternoon Tea		
15.40 - 16.05	Poster Tour 02 Location: Posters 4 - 8		
16.15 - 17.45	Session J: Peer workers on sharing and censoring their stories of stigma Room: Ballroom 2	16.15 - 17.45	Session K: Models of Care in Different Settings Room: Ballroom 3
19.00 - 23.00	Conference Dinner The Warehouse		

PROGRAM

DAY 3: TUESDAY 31 MAY

Full details on the presentations and speakers can be found in the conference app.

08.30	Registration Opens		
09.00 - 10.45	Session L: Plenary 03 Room: Ballroom 3		
10.45 - 11.30	Morning Tea		
10.55 - 11.20	Poster Tour 03 Location: Posters 9 - 12		
11.30 - 13.00	Session M: Evolving technologies and viral hepatitis care Room: Ballroom 2	11.30 - 13.00	Session N: Tales from the Top End Room: Ballroom 3
13.00 - 14.30	Lunch		
13.20 - 13.45	Session O: Multimedia Session Room: Ballroom 2	13.15 - 13.45	ILBIJERRI Theatre Company's VIRAL: Are You The Cure? Room: Ballroom 3
		13.45 - 14.20	VitalvoicesofhepC.org - Personal stories of treatment for hepatitis C - New website launch Room: Ballroom 3
14.30 - 15.35	Session P: Proffered Paper Session 04 Room: Ballroom 2	14.30 - 15.35	Session Q: Proffered Paper Session 05 Room: Ballroom 3
15.35 - 16.00	Afternoon Tea		
16.00 - 17.00	Session R: Closing Plenary Room: Ballroom 3		

POSTER LISTING

Poster Tour 01

#01 Trust in healthcare providers among Chinese immigrants living with hepatitis B virus in Australia: A qualitative study

Defeng Jin, Centre for Social Research in Health, UNSW

Discipline: Social and Community Research

#02 Stigma's impact on treatment – a bilingual community health worker's experience

Christine Olango, Ethnic Communities Council of Queensland

Discipline: Other

#03 An evaluation of Hepatitis Queensland's Community Corrections Hepatitis C clinics

Linda Selvey, School Of Public Health, The University Of Queensland

Discipline: Social and Community Research

Poster Tour 02

#04 Access, Care and Empowerment (ACE) mobile app for people who inject drugs in Western Australia

Judith Bevan, Department of Health WA

Discipline: Social and Community Research

#05 Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study

Syed Hassan Bin Usman Shah, The Kirby Institute

Discipline: Epidemiology and Public Health

#06 Performance of an Ultra-sensitive HBsAg Assay

Kathy Jackson, Victorian Infectious Diseases Reference Laboratory

Discipline: Biomedical and Clinical

#07 Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander people with HCV infection: analysis of a national real-world cohort (REACH-C)

Jessica Buhagiar, UNSW / The Kirby Institute

Discipline: Biomedical and Clinical

#08 A novel testing modality to address barriers to hepatitis c testing and treatment among Aboriginal and Torres Strait Islander people in New South Wales, Australia: The NSW DBS pilot study

Nigel Carrington, NSW Ministry Of Health

Discipline: Epidemiology and Public Health

Poster Tour 03

#09 Clinical characteristics of sex workers and men who have sex with men, living with CHB, attending a publicly funded sexual health service

Anik Ray, Sydney Sexual Health Centre

Discipline: Biomedical and Clinical

#10 Love your liver with good nutrition

Tracey Jones, Justice Health and Forensic Mental Health Network

Discipline: Biomedical and Clinical

#11 Describing client presentations at four syringe dispensing machines in South-East Melbourne, Australia

Phoebe Kerr, Burnet Institute

Discipline: Epidemiology and Public Health

#12 Coordinated Hepatitis responses to Enhance the Cascade of Care by optimising Existing Surveillance Systems (CHECCS) in Victoria

Mielle Abbott, WHO Collaborating Centre For Viral Hepatitis at The Doherty Institute

Discipline: Epidemiology and Public Health

Other

#13 Knowledge, Attitudes, Practices and Educational Needs Toward Hepatitis B Virus in Arab Communities: A National Study in Oman

Omar Al Zaabi, Department of Adult Health and Critical Care, College of Nursing, SQU, Muscat, Oman

Discipline: Epidemiology and Public Health

#14 HepLOGIC: a primary care intervention to improve viral hepatitis and liver cancer outcomes – pilot and feasibility study

Nicole Allard, Who Collaborating Centre For Viral Hepatitis, The Doherty Institute

Discipline: Biomedical and Clinical

#15 Can the offer of financial incentives improve the uptake of treatment for hepatitis C?

Nada Andric, The Exodus Foundation Clinic

Discipline: Epidemiology and Public Health

#16 nTASH-C (nonTArgeted Screening in Hepatitis C) High prevalence of hepatitis C virus infection in non-risk factor-based screening settings

Asma Baig, Blacktown Hospital

Discipline: Epidemiology and Public Health

#17 4 years on. Providing GPs access to Fibroscan for CALD community members affected by viral hepatitis in South East Queensland

Marrianne Black, Ethnic Communities Council of Queensland

Discipline: Epidemiology and Public Health

#18 Implementation of dried blood spot testing for HIV and hepatitis C: the NSW DBS pilot study - a client-centred alternative to traditional health care

Nigel Carrington, NSW Ministry Of Health

Discipline: Epidemiology and Public Health

#19 Never fear- polar is here; a nationally available tool for chronic hepatitis c management in general practice

Phoebe Chomley, Central and Eastern Sydney PHN

Discipline: Epidemiology and Public Health

#20 Building capacity and enthusiasm to evaluate hepatitis C elimination strategies in community organisations: learnings from a national implementation program.

Joshua Dawe, Burnet Institute

Discipline: Social and Community Research

#21 Hepatocellular Carcinoma Surveillance for Viral Hepatitis and Cirrhotic Patients in Primary Care: a Systematic Review of the Evidence

*Barbara De Graaff,
Menzies Institute for
Medical Research*

*Discipline: Epidemiology
and Public Health*

#22 Sharing liver health resources for young people

Kay Duffy, LiverWELL

Discipline: Other

#23 Significantly lower hepatocellular carcinoma screening uptake in populations with low socio-economic profiles

Kathryn Gazelakis, Western Health

*Discipline: Epidemiology
and Public Health*

#24 The impact of hepatitis B virus genotype on disease manifestations among Aboriginal and Torres Strait islander Australians in Far North Queensland

*Joshua Hanson,
Cairns Hospital*

*Discipline: Epidemiology
and Public Health*

#25 Global Unification for World Hepatitis Day: An effective strategy for Australian action and engagement

*Grace Hogan,
Hepatitis Australia*

Discipline: Other

#26 Validation of a novel point-of-care ALT1 test in patients with viral hepatitis: a pilot cohort study

*Jessica Howell, St Vincent's
Hospital Melbourne*

*Discipline: Biomedical
and Clinical*

#27 Using dimeric to monomeric IgA ratio to diagnose portal hypertension in viral hepatitis: a pilot cohort study

*Jessica Howell, St Vincent's
Hospital Melbourne*

*Discipline: Biomedical
and Clinical*

#28 Connecting Hepatitis B Patients in the era of COVID-19: Hep B Writing Competition in Language

*Mina (Ji Hyun) Kim,
Hepatitis NSW*

Discipline: Other

#29 Hepatitis C Direct-Acting Antiviral treatment completion: comparison of geographic, demographic, and clinical characteristics in Australia

*Jennifer Maclachlan,
Who Collaborating Centre
For Viral Hepatitis,
The Doherty Institute*

*Discipline: Epidemiology
and Public Health*

#30 Supporting GPs to increase confidence in testing and treating Hepatitis C

*Emelie Malmqvist, NSW
Ministry Of Health*

*Discipline: Social and
Community Research*

#31 Active case management to connect hepatitis C notifications to care and treatment in Australia (CONNECT study), a randomised controlled trial

*Tafireyi Marukutira,
Macfarlane Burnet Institute*

*Discipline: Epidemiology
and Public Health*

#32 Thinking outside the square' in providing viral hepatitis education and medical history assessment in a pandemic: The New Zealand perspective

*Lynnaire Matthews, The
Hepatitis Foundation of NZ*

*Discipline: Epidemiology
and Public Health*

#33 “There’s too many steps when people are homeless” barriers and enablers to hepatitis C treatment among people who are homeless and unstably housed

Roisin McColl, Who Collaborating Centre For Viral Hepatitis, The Doherty Institute

Discipline: Social and Community Research

#34 An Aboriginal community resource “Yarnin; about hep B”

Maria McMahon, Hepatitis NSW

Discipline: Other

#35 Hepatitis B Education and the Australian Migrant English Program (AMEP)

Alain Palines, LiverWELL

Discipline: Other

#36 Getting pricked for Hep C: Piloting Dried Blood Spot testing within an Aboriginal Healthy Lifestyle Program in South Eastern Sydney

Tiana Parashko, SESLHD HIV&Related Programs (HARP)

Discipline: Social and Community Research

#37 NSW Needle and Syringe Program Review

Kate Patten, NSW Ministry Of Health

Discipline: Epidemiology and Public Health

#38 Beer and wine are not “Alcohol”

Evelyn Pe, Ethnic Communities Council of Queensland

Discipline: Other

#39 Drug use harm reduction messages delivered in colourful, graphical, fit pack stickers and comics for people living with hepatitis C

Chloe Pedley, LiverWELL

Discipline: Other

#40 Reconfiguring Chronic Disease Self-Management Programs for better management of viral hepatitis and other chronic liver conditions

Pearl Prabal, Liverwell Incorporating Hepatitis Victoria

Discipline: Other

#41 Time to Reflect, Review, Revise, and Renew the Hepatitis Nursing Model of Care

Janice Pritchard-Jones, G&I, SLhd

Discipline: Epidemiology and Public Health

#42 A novel multidisciplinary approach to Chronic Hepatitis B care – reducing barriers to access and increasing engagement with sex workers and men who have sex with men who are culturally and linguistically diverse

Anik Ray, Sydney Sexual Health Centre

Discipline: Biomedical and Clinical

#43 Evaluation of Hepatitis C peer support workers project

Linda Selvey, School Of Public Health, The University Of Queensland

Discipline: Social and Community Research

#44 Using Queensland Health notifications data to increase hepatitis C treatment

Linda Selvey, School Of Public Health, The University Of Queensland

Discipline: Epidemiology and Public Health

#45 Incentivising HCV testing and treatment in community health clinics, a qualitative evaluation

Linda Selvey, School Of Public Health, The University Of Queensland

Discipline: Epidemiology and Public Health

#46 Time to Reflect, Review, Revise, and Renew the Hepatitis Nursing Model of Care

Keren Smart, Hepatitis Queensland

Discipline: Other

#47 Information for Action: Developing an Operational Guide to assist countries in collecting monitoring and evaluation indicators for viral hepatitis

Zoe Stephens, Victorian Infectious Diseases Reference Laboratory

Discipline: Epidemiology and Public Health

#48 Hepatitis C Elimination in NSW by 2028 – Priming the System to Deliver Change

Annabelle Stevens, NSW Ministry Of Health

Discipline: Epidemiology and Public Health

#49 Setting Targets towards Elimination – Monitoring NSW Progress

Annabelle Stevens, NSW Ministry Of Health

Discipline: Epidemiology and Public Health'

#50 Towards elimination through the NSW Hepatitis C Remote Prescribing Program

Jana van der Jagt, Mid North Coast Local Health District

Discipline: Biomedical and Clinical

#51 Social Media Underpinning Digital Pathways to Hep C Elimination

Susanne Wilkinson, Hepatitis NSW

Discipline: Epidemiology and Public Health

#52 A pragmatic approach to Harm Reduction in Prisons

Thomas Wright, Justice Health and Forensic Mental Health Network

Discipline: Epidemiology and Public Health

#53 Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis


Mohammad Tahir Yousafzai, UNSW The Kirby Institute

Discipline: Epidemiology and Public Health

VIRTUAL #54 Adapting viral hepatitis services in the face of COVID-19 pandemic in Myanmar: lessons from a network of non-governmental clinics

Win Lei Yee, Burnet Institute

Discipline: Epidemiology and Public Health



vh2022

hepatitis.org.au

@ashmmedia

#VH2022

